Washington, DC, United States
Washington, DC, United States

Georgetown University is a private research university in Washington, D.C. Founded in 1789, it is the oldest Catholic college or university in the United States, and so the oldest Jesuit university in the country. Georgetown's main campus, located in Washington's Georgetown neighborhood, is noted for Healy Hall, a National Historic Landmark in the Romanesque revival style. Georgetown Law School is located on Capitol Hill and Georgetown has auxiliary campuses in Italy, Turkey, and Qatar.Georgetown's founding by John Carroll, as America's first Catholic bishop, realized earlier efforts to establish a Roman Catholic college in the province of Maryland that had been thwarted by religious persecution. The university expanded after the American Civil War under the leadership of Patrick Francis Healy, who came to be known as Georgetown's "second founder" despite having been born a slave by law. Jesuits have participated in the university's administration since 1805, a heritage Georgetown celebrates, but the university has always been governed independently of the Society of Jesus and of church authorities.The university has about 7,000 undergraduate and over 10,000 post-graduate students from a wide variety of religious, ethnic, and geographic backgrounds, including 130 foreign countries. The university's most notable alumni are prominent in public life in the United States and abroad. Among them are former U.S. President Bill Clinton, U.S. Supreme Court Associate Justice Antonin Scalia, dozens of U.S. governors and members of Congress, heads of state or government of more than a dozen countries, royalty and diplomats.Campus organizations include the country's largest student-run business and largest student-run financial institution. Georgetown's athletic teams, nicknamed the Hoyas, include a men's basketball team that has won a record-tying seven Big East championships, appeared in five Final Fours, and won a national championship in 1984. Wikipedia.


Time filter

Source Type

A device for introducing at least one antimicrobial in an exposed region of a users skin caused while accessing interstitial fluid includes a substrate having thereon at least one electrically controllable microheating element including at least a microheater portion with multiple electrodes connected to the microheater portion for forming a micropore in the users skin. A nanofiber mat loaded with at least one antimicrobial material is arranged on the substrate such that it contacts the users skin and encircles an opening of the micropore formed by the microheating element. In a preferred embodiment, the at least one antimicrobial material is LL-37.


Patent
Georgetown University and Duke University | Date: 2016-04-05

Disclosed are heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. The compounds are useful for treating a mammal suffering from any one of a range of therapeutic indications, including Alzheimers disease, Parkinsons disease, dyskinesias, Tourettes syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Gansers syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism, trichotillomania, and hypothermia.


Patent
Georgetown University | Date: 2016-12-12

Methods of treating or preventing cancer and/or a neurodegenerative disorder in a subject are provided. The methods comprise administering to a subject a therapeutically effective amount of 1,2,3-benzenetricarboxylic acid or a hydrate or pharmaceutically acceptable salt thereof.


Patent
Georgetown University | Date: 2016-11-02

The present invention relates to orthotic devices and footwear. In particular, the present invention relates to orthotic devices comprising a wedge configured to be placed beneath a forefoot.


Patent
Georgetown University and University of Rochester | Date: 2015-04-30

The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subjects lipidomic profile, and also analyzing the gene expression profile from leukocytes and comparing the value of the subjects biomarker profile (lipidomic profile plus gene expression profile) with the value of a normal biomarker profile. A change in the value of the subjects biomarker profile, including a change in the subjects biomarker profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.


Cheson B.D.,Georgetown University
Journal of Clinical Oncology | Year: 2010

The availability of safe and effective monoclonal antibodies (mAbs) has dramatically altered treatment strategies for B-cell malignancies. Rituximab, a type I chimeric anti-CD20 mAb, not only has activity against a broad range of CD20-positive B-cell malignancies but also, when combined with chemotherapy or other biologic agents, has improved response rates; in addition, in certain situations, progression-free survival and even overall survival may be prolonged. Recently, other anti-CD20 mAbs have been developed to improve on the activity achieved with rituximab or to demonstrate efficacy in patients whose diseases are resistant to rituximab. The most extensively studied of these is ofatumumab, a type I human antibody that binds to a different epitope of CD20 than rituximab. Preclinical data suggest improved complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity compared with rituximab. In early clinical trials, ofatumumab demonstrated single-agent activity against chronic lymphocytic leukemia (CLL) and a number of histologies of B-cell non-Hodgkin's lymphomas. This antibody was recently approved by the US Food and Drug Administration for the treatment of CLL that is resistant to both fludarabine and alemtuzumab. Additional study is ongoing with ofatumumab in combination with chemotherapy and biologic agents to further enhance its efficacy. Ofatumumab offers another effective agent with which to improve the outcome of patients with B-cell malignancies. © 2010 by American Society of Clinical Oncology.


Gostin L.O.,Georgetown University
JAMA - Journal of the American Medical Association | Year: 2012

Health inequalities represent perhaps the most consequential global health challenge and yet they persist despite increased funding and innovative programs. The United Nations is revising the Millennium Development Goals (MDGs) that will shape the world for many years to come. What would a transformative post-MDG framework for global health justice look like? A global coalition of civil society and academics - the Joint Action and Learning Initiative on National and Global Responsibilities for Health (JALI) - has formed an international campaign to advocate for a Framework Convention on Global Health (FCGH). Recently endorsed by the UN Secretary-General, the FCGH would reimagine global governance for health, offering a new post-MDG vision. This Special Communication describes the key modalities of an FCGH to illustrate how it would improve health and reduce inequalities. The modalities would include defining national responsibilities for the population's health; defining international responsibilities for reliable, sustainable funding; setting global health priorities; coordinating fragmented activities; reshaping global governance for health; and providing strong global health leadership through the World Health Organization. ©2012 American Medical Association. All rights reserved.


Weiss R.G.,Georgetown University
Journal of the American Chemical Society | Year: 2014

A Perspective is presented on the history and current understanding of molecular gels and the factors that must be considered to characterize them. The abilities of the most important structural, dynamic, and rheological tools available currently to provide the information necessary to follow the formation of a molecular gel from its initial sol phase and then to define it at different distance and time scales are discussed. Approaches to determining a priori when a molecule will gelate a selected liquid, as well as possible methodologies for overcoming current limitations in understanding molecular gels, are presented. Finally, some of the many potential and realized applications for these materials are enumerated. © 2014 American Chemical Society.


Tong Y.J.,Georgetown University
Chemical Society Reviews | Year: 2012

Promoters and poisons for catalytic activity have been a subject of intensive research in both heterogeneous catalysis and electrocatalysis for decades, driven primarily by profound financial and societal implications involved because catalyzed reactions are at the center of many enterprises of chemical and petroleum industries. Consequently, there exist well-identified promoters and poisons, such as electropositive alkali elements for the former and electronegative later 2p elements for the latter, respectively. Research on catalytic promoters or poisons has traditionally been along the lines of these conventional classifications of promoters vs. poisons. However, this short Critical Review will not follow such traditional lines of reasoning, i.e., to discuss how the well-identified promoters can be better utilized and/or how the equally well-identified poisons can be eliminated or better tolerated. Rather, it will focus on cases that highlight an emerging area of research in which many traditional poisoning species have been used to promote catalytic activity, which include recent work on using sulfur and poly(vinylpyrrolidone) (PVP) as catalytic promoters carried out in the author's lab. © 2012 The Royal Society of Chemistry.


Mitchell J.M.,Georgetown University
New England Journal of Medicine | Year: 2013

BACKGROUND: Some urology groups have integrated intensity-modulated radiation therapy (IMRT), a radiation treatment with a high reimbursement rate, into their practice. This is permitted by the exception for in-office ancillary services in the federal prohibition against self-referral. I examined the association between ownership of IMRT services and use of IMRT to treat prostate cancer. METHODS: Using Medicare claims from 2005 through 2010, I constructed two samples: one comprising 35 self-referring urology groups in private practice and a matched control group comprising 35 non-self-referring urology groups in private practice, and the other comprising non-self-referring urologists employed at 11 National Comprehensive Cancer Network centers matched with 11 self-referring urology groups in private practice. I compared the use of IMRT in the periods before and during ownership and used a difference-in-differences analysis to evaluate changes in IMRT use according to self-referral status. RESULTS: The rate of IMRT use by self-referring urologists in private practice increased from 13.1 to 32.3%, an increase of 19.2 percentage points (P<0.001). Among non-self-referring urologists, the rate of IMRT use increased from 14.3 to 15.6%, an increase of 1.3 percentage points (P = 0.05). The unadjusted difference-in-differences effect was 17.9 percentage points (P<0.001). The regression-adjusted increase in IMRT use associated with self-referral was 16.4 percentage points (P<0.001). The rate of IMRT use by urologists working at National Comprehensive Cancer Network centers remained stable at 8.0% but increased by 33.0 percentage points among the 11 matched self-referring urology groups. The regressionadjusted difference-in-differences effect was 29.3 percentage points (P<0.001). CONCLUSIONS: Urologists who acquired ownership of IMRT services increased their use of IMRT substantially more than urologists who did not own such services. Allowing urologists to self-refer for IMRT may contribute to increased use of this expensive therapy. Copyright © 2013 Massachusetts Medical Society.

Loading Georgetown University collaborators
Loading Georgetown University collaborators